×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
NASDAQ:LIVN

LivaNova (LIVN) Stock Forecast, Price & News

$67.53
+1.51 (+2.29%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$66.03
$67.66
50-Day Range
$58.96
$86.63
52-Week Range
$58.18
$93.89
Volume
228,156 shs
Average Volume
342,926 shs
Market Capitalization
$3.61 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.91
30 days | 90 days | 365 days | Advanced Chart
Receive LIVN News and Ratings via Email

Sign-up to receive the latest news and ratings for LivaNova and its competitors with MarketBeat's FREE daily newsletter.

LivaNova logo

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

Headlines

LivaNova (NASDAQ:LIVN) Hits New 12-Month Low at $58.18
See More Headlines

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LIVN
Employees
3,000
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.04 billion
Cash Flow
$3.77 per share
Book Value
$24.17 per share

Profitability

Net Income
$-135.82 million
Pretax Margin
-8.84%

Debt

Price-To-Earnings

Miscellaneous

Free Float
53,243,000
Market Cap
$3.61 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/29/2022
Next Earnings (Estimated)
7/27/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.51 out of 5 stars

Medical Sector

133rd out of 1,424 stocks

Electromedical Equipment Industry

3rd out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -













LivaNova (NASDAQ:LIVN) Frequently Asked Questions

Is LivaNova a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LivaNova stock.
View analyst ratings for LivaNova
or view top-rated stocks.

When is LivaNova's next earnings date?

LivaNova is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for LivaNova
.

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) announced its quarterly earnings results on Wednesday, May, 4th. The company reported $0.48 earnings per share for the quarter, hitting the consensus estimate of $0.48. The business earned $240.20 million during the quarter, compared to the consensus estimate of $231.57 million. LivaNova had a negative net margin of 9.69% and a positive trailing twelve-month return on equity of 9.57%. The business's quarterly revenue was down 3.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.35 EPS.
View LivaNova's earnings history
.

What guidance has LivaNova issued on next quarter's earnings?

LivaNova updated its FY 2022 earnings guidance on Wednesday, May, 11th. The company provided earnings per share guidance of $2.50-$2.80 for the period, compared to the consensus earnings per share estimate of $2.59. The company issued revenue guidance of $1.07 billion-$1.09 billion, compared to the consensus revenue estimate of $1.04 billion.

What price target have analysts set for LIVN?

6 analysts have issued twelve-month price targets for LivaNova's shares. Their forecasts range from $95.00 to $108.00. On average, they anticipate LivaNova's stock price to reach $101.50 in the next twelve months. This suggests a possible upside of 50.3% from the stock's current price.
View analysts' price targets for LivaNova
or view top-rated stocks among Wall Street analysts.

Who are LivaNova's key executives?
LivaNova's management team includes the following people:
  • Mr. Damien McDonald, CEO & Director (Age 57, Pay $1.28M)
  • Mr. Alex Shvartsburg, CFO and Corp. VP of Financial Planning, Analysis & International Region (Age 52, Pay $445.29k)
  • Ms. Keyna Pidcock Skeffington, Sr. VP, Gen. Counsel & Corp. Sec. (Age 59, Pay $623.28k)
  • Mr. Marco Dolci, Pres of Cardiopulmonary (Age 59, Pay $744.15k) (LinkedIn Profile)
  • Deanna Wilke, Director of Corp. Communications
  • Mr. Matthew Joseph Dodds III, Sr. VP of Corp. Devel.
  • Ms. Trui Hebbelinck, Chief HR Officer (Age 50)
  • Dr. Bryan D. Olin Ph.D., Sr. VP & Head of Product Devel. - Neuromodulation (Age 55)
  • Mr. Paul R. Buckman, Pres of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement (Age 66)
  • Mr. Ryan Miller, Sr. VP of Strategy
What is Damien McDonald's approval rating as LivaNova's CEO?

47 employees have rated LivaNova CEO Damien McDonald on Glassdoor.com. Damien McDonald has an approval rating of 77% among LivaNova's employees.

What other stocks do shareholders of LivaNova own?
What is LivaNova's stock symbol?

LivaNova trades on the NASDAQ under the ticker symbol "LIVN."

Who are LivaNova's major shareholders?

LivaNova's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.78%), Primecap Management Co. CA (8.47%), Harris Associates L P (7.25%), State Street Corp (4.44%), Eminence Capital LP (3.65%) and Vanguard Group Inc. (2.52%). Company insiders that own LivaNova stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore and Marco Dolci.
View institutional ownership trends for LivaNova
.

Which major investors are selling LivaNova stock?

LIVN stock was sold by a variety of institutional investors in the last quarter, including Paradice Investment Management LLC, Arrowstreet Capital Limited Partnership, Federated Hermes Inc., Renaissance Technologies LLC, BlackRock Inc., Polar Capital Holdings Plc, Mirabella Financial Services LLP, and State Street Corp. Company insiders that have sold LivaNova company stock in the last year include Alfred J Novak, Damien Mcdonald, and Daniel Jeffrey Moore.
View insider buying and selling activity for LivaNova
or view top insider-selling stocks.

Which major investors are buying LivaNova stock?

LIVN stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Goldman Sachs Group Inc., Eminence Capital LP, Primecap Management Co. CA, Greenlight Capital Inc., Loomis Sayles & Co. L P, Victory Capital Management Inc., and Teacher Retirement System of Texas.
View insider buying and selling activity for LivaNova
or or view top insider-buying stocks.

How do I buy shares of LivaNova?

Shares of LIVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LivaNova's stock price today?

One share of LIVN stock can currently be purchased for approximately $67.53.

How much money does LivaNova make?

LivaNova has a market capitalization of $3.61 billion and generates $1.04 billion in revenue each year. The company earns $-135.82 million in net income (profit) each year or ($1.990010) on an earnings per share basis.

How many employees does LivaNova have?

LivaNova employs 3,000 workers across the globe.

What is LivaNova's official website?

The official website for LivaNova is www.livanova.com.

How can I contact LivaNova?

LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company can be reached via phone at 442033250660, via email at [email protected], or via fax at 281-218-9332.

This page was last updated on 5/29/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.